(RTTNews) - Shares of Eiger BioPharmaceuticals, Inc. (EIGR) are climbing more than 8% Thursday morning after the company announced positive results from the study of its antiviral therapy in Covid-19 patients.
The study called ILIAD (Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in Covid-19)in outpatients with mild to moderate Covid-19 showed that the SARS-CoV-2 RNA viral load decline from baseline was significantly greater in the Lambda group than in the placebo group from day 5 on wards.
EIGR stock is currently trading at $9.35. It has traded in the range of $4.55- $15.82 in the last one year.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.